Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - Change in substantial holding (ASX:IMM)

To view the notice of change of interests of substantial holder, download the attached PDF.

Immutep - Half Yearly Report and Accounts (ASX:IMM)

To view the report, download the attached PDF.

Immutep reports positive TACTI-002 data (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, an...read more

Ingenia Communities Group - 1H20 Property Portfolio (ASX:INA)

Ingenia Communities Group (INA) provides its 1H20 Property Portfolio which is authorised for release by the Ingenia Communities Group Company Secretary. For more information, download the attache...read more

Ingenia Communities Group - 1H20 Results Presentation (ASX:INA)

To view the presentation, download the attached PDF.

Ingenia Communities Group - Portfolio expansion delivers 40% EBIT growth with stronger rental base (ASX:INA)

Ingenia Communities Group (ASX: INA) today announced Underlying Profit of $26.5 million for the half year ending 31 December 2019, an increase of 52% on the previous corresponding period. Statutory ...read more

Ingenia Communities Group - Dividend/Distribution (ASX:INA)

To view the notification of dividend/distribution, download the attached PDF.

Ingenia Communities Group - Appendix 4D and Half Year Accounts (ASX:INA)

Ingenia Communities Group (INA) provides its Appendix 4D which is authorised for release by the Ingenia Communities Group Board. To view the appendix, download the attached PDF.

Change in substantial holding (ASX:IMM)

For more information, please download the attached PDF

Immutep to present TACTI-002 data at German Cancer Congress (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, ad...read more

InPayTech Quaterly Report (ASX:IP1)

For the full report, please download the attached PDF

Appendix 4C-Quarterly report for entities subject to Listing Rule 4.7B (ASX:IP1)

For more information, please download the attached PDF

Quarterly Activities and Cash Flow Report Quarter ended 31 December 2019 (ASX:IMU)

Key Highlights: Imugene completes oversubscribed placement of $24.6 million to fund clinical programs on 02- December, 2019 Professor Yuman Fong appointed Chairman of the Oncolytic Virotherapy S...read more

Immutep Activities Report (ASX:IMM)

Highlights: First progression-free survival (“PFS”) data expected from late-stage Phase IIb metastatic breast cancer study, AIPAC, in March 2020 More mature data expected from TACTI-...read more